Pfizer Ltd’s Patient Advocacy Group Disclosure 2014

Action Duchenne Limited

Action Duchenne Limited works across the UK to improve the lives of those affected by Duchenne and Becker Muscular Dystrophy, whilst supporting innovative research into a cure and effective new medicines.

During 2014, Pfizer supported Action Duchenne Limited with the following:

- We made a donation in support of the International Action Duchenne Conference hosted by Action Duchenne Limited. £2,600

During 2014, Pfizer contracted the following services from Action Duchenne Limited:

- We paid for the registration of two Pfizer colleagues to attend the Action Duchenne international conference. £400

Total: £3,000

As a guide this amount represents less than 1% of the total income of Action Duchenne Limited based on its last reported financial year (November 2012 - October 2013).

Action on Pain

Action on Pain provides advice and support to people living with pain and strives to raise the profile of pain among politicians, the NHS and healthcare professionals.

During 2014, Pfizer supported Action on Pain with the following:

- We made a donation in support of the printing of leaflets and display panels for patients with chronic pain. £2,750

Total: £2,750

As a guide this amount represents 11% of the total income of Action on Pain based on its last reported financial year (October 2012 - September 2013).

Age Concern Cowplain

Age Concern aims to improve later life for everyone through services and facilities for the wellbeing of older people in local areas.

During 2014, Pfizer supported Age Concern with the following:

- We made a donation to support a volunteer recruitment day for the organisation’s befriending service, which aims to get socially isolated and lonely older persons back out into their local communities. £300

Total: £300
As a guide this amount represents less than 1% of the total income of Age Concern Cowplain based on its last reported financial year (July 2013 - June 2014).

**Anthony Nolan**

Anthony Nolan saves the lives of people with blood cancer who need a blood stem cell or bone marrow transplant. They match patients with donors through their donor register, to facilitate potentially lifesaving transplants every day. They also conduct groundbreaking research to improve the success rate of transplants and provide support, advice and information for people with blood cancer and their families.

During 2014, Pfizer supported Anthony Nolan with the following:  

- We provided sponsorship for Anthony Nolan’s annual transplant clinician’s update meeting in 2014.

**Sum received by the organisation**

£10,000

**Total**: £10,000

As a guide this amount represents less than 1% of the total income of Anthony Nolan based on its last reported financial year (April 2013 – March 2014).

**AntiCoagulation Europe**

AntiCoagulation Europe is a UK registered charity founded in the year 2000. AntiCoagulation Europe works with patients, healthcare professionals, NHS trusts, industry, governments, other charities and patient groups and a wide range of other organisations. Its aims are: the prevention of thrombosis; the provision of information, education and support; the promotion of independence - supporting people to take an active part in their own healthcare.

During 2014, Pfizer supported AntiCoagulation Europe with the following:  

- The BMS-Pfizer Alliance (an alliance between Bristol-Myers Squibb Pharmaceuticals Ltd and Pfizer Ltd) made a donation towards the costs of Anticoagulation Europe’s regional patient education meetings.
- The BMS-Pfizer Alliance provided funding to enable Anticoagulation Europe to provide the Secretariat to the All-Party Parliamentary Group on Thrombosis for the first half of 2014.
- The BMS-Pfizer Alliance paid for two delegate places at the Anticoagulation in Practice meeting for healthcare professionals, which is organised by Anticoagulation Europe.

**Sum received by the organisation**

£9,750*

£7,500*

£162.50*

**Total**: £17,412.50

As a guide this amount represents 14.2% of the total income of AntiCoagulation Europe based on its last reported financial year (January – December 2013).

*Amounts shown are Pfizer’s contribution to the total payment from the BMS-Pfizer Alliance, which was 50% in all cases.
**Arrhythmia Alliance**

Arrhythmia Alliance (A-A) is a coalition of charities, patient groups, patients, carers, medical groups and allied professionals. These groups remain independent, however, working together under the A-A umbrella to promote timely and effective diagnosis and treatment of arrhythmias.

During 2014, Pfizer supported the Arrhythmia Alliance with the following:

- The BMS-Pfizer Alliance (an alliance between Bristol-Myers Squibb Pharmaceuticals Ltd and Pfizer Limited) paid for sponsorship of the Arrhythmia Alliance’s Cardiac Update meeting series for healthcare professionals in 2013 and 2014 (2013 payment made in 2014).
  
  £10,000*  

- The BMS-Pfizer Alliance paid for sponsorship of the Arrhythmia Alliance’s 10th Anniversary parliamentary event in Westminster.
  
  £175.00*  

- The BMS-Pfizer Alliance made a donation towards the Arrhythmia Alliance’s organisation of a launch event in the EU Parliament in Brussels, and European-wide roll-out, of a report on Atrial Fibrillation in Europe.
  
  £33,750*  

Total: £43,925  

As a guide this amount represents 4.1% of the total income of the Arrhythmia Alliance based on its last reported financial year (January – December 2013).  

*Amounts shown are Pfizer’s contribution to the total payment from the BMS-Pfizer Alliance, which was 50% in all cases.

**Arthritis and Musculoskeletal Alliance (ARMA)**

ARMA is the umbrella body providing a collective voice for the arthritis and musculoskeletal community in the UK. Together, ARMA and its member organisations work to improve the quality of life for more than 10 million people in the UK with these conditions. ARMA has 40 member organisations representing a broad range of interests across service user, professional and research groups working in the field of musculoskeletal disorders.

During 2014, Pfizer supported ARMA with the following:

- We made a donation in support of the ‘Bone & Joint Decade’ conference organised by ARMA.
  
  £6,000  

Total: £6,000  

As a guide this amount represents 3.5% of the total income of ARMA based on its last reported financial year (January – December 2013).

**Arthritis Research UK**

Arthritis Research UK are working to take the pain away from people living with all forms of arthritis and helping them to remain active. Arthritis Research UK fund research, educate health care professionals and provide information to people with arthritis and their carers.
During 2014, Pfizer provided Arthritis Research UK with in-kind support in the following way:

- We provided two delegate places at a Pfizer organised ‘Inflammation Competitive Research Programme’ investigator meeting held in London in September 2014.

Total: £0

Atrial Fibrillation Association (AF Association)

The AF Association is an international charity which provides information, support and access to established, new or innovative treatments for atrial fibrillation (AF).

During 2014, Pfizer supported the AF Association with the following:

- The BMS-Pfizer Alliance made a donation towards the costs of the AF Association’s regional patient education programme on AF.

During 2014, Pfizer contracted the following services from the AF Association:

- The BMS-Pfizer Alliance paid an honorarium for the participation of an AF Association staff member in a BMS-Pfizer Alliance European Advisory Board meeting which took place in the UK. £215.00*
- The BMS-Pfizer Alliance paid an honorarium for the participation of an AF Association staff member in a BMS-Pfizer Alliance European Advisory Board meeting which took place in the UK. £215.00*
- The BMS-Pfizer Alliance paid an honorarium for the participation of an AF Association staff member in a BMS-Pfizer Alliance European Advisory Board meeting which took place in the UK. £215.00*
- The BMS-Pfizer Alliance paid an honorarium for the participation of an AF Association staff member in a BMS-Pfizer Alliance European Advisory Board meeting which took place in the UK. £215.00*
- The BMS-Pfizer Alliance paid an honorarium for preparation time and participation of an AF Association staff member in a BMS-Pfizer Alliance Patient Group Summit which took place in Europe. £690.00*
- The BMS-Pfizer Alliance paid expenses for one AF Association staff member in relation to their participation in a BMS-Pfizer Alliance Patient Group Summit which took place in Europe: Flights = £188.50 / Accommodation = £44.50 / Transfers = £45.14. £0
- We paid an honoraria for the participation of an AF Association staff member in a media roundtable on atrial fibrillation. £750
- We contracted with the AF Association to provide a speaker at a Pfizer organised roundtable meeting on Informed Choice in the NHS. £0

Total: £32,300

As a guide this amount represents 13.5% of the total income of the AF Association based on its last reported financial year (January – December 2013).

*Amounts shown are Pfizer’s contribution to the total payment from the BMS-Pfizer Alliance, which was 50% in all cases.
ASH Wales

ASH Wales is the leading voluntary organisation in Wales tackling tobacco use. Their main aim is to achieve a reduction in and eventual elimination of the health problems associated with tobacco use.

During 2014, Pfizer supported ASH Wales with the following:

- We made a charitable donation in support of the organisation’s Wales Tobacco or Health Network meeting.

<table>
<thead>
<tr>
<th>Sum received by the organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>£2,000</td>
</tr>
</tbody>
</table>

Total: £2,000

As a guide this amount represents less than 1% of the total income of ASH Wales based on its last reported financial year (October 2012 - September 2013).

Ataxia UK

Ataxia UK works across the UK to support people with ataxia, their families, carers and friends; they fund research into developing safe, effective treatments and help people to live with ataxia.

During 2014, Pfizer supported Ataxia UK with the following:

- We made a donation in support of the 2015 International Ataxia Research Conference hosted by Ataxia UK.
- We made a donation to support the registration fees of two attendees for the 2015 International Research Conference.

<table>
<thead>
<tr>
<th>Sum received by the organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>£4,500</td>
</tr>
<tr>
<td>£480</td>
</tr>
</tbody>
</table>

Total: £4,980

As a guide this amount represents less than 1% of the total income of Ataxia UK based on its last reported financial year (April 2013 - March 2014).

BackCare

BackCare, the charity for healthier backs, is the only charity in the UK totally dedicated to providing support for, and campaigning on behalf of, people whose lives are significantly affected by back pain.

During 2014, Pfizer supported BackCare with the following:

- We made a donation in support of the redesign of the BackCare website.

<table>
<thead>
<tr>
<th>Sum received by the organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>£3,000</td>
</tr>
</tbody>
</table>

Total: £3,000

As a guide this amount represents less than 1% of the total income of BackCare based on its last reported financial year (October 2012 - September 2013).

Pfizer also provided in-kind support in the following ways:

- We donated the Pain Exchange website to BackCare which allows members of the public to share their experiences of living with chronic or persistent pain. The website was originally designed and run by Pfizer in 2013 and ownership was transferred to BackCare in 2014.
**Breast Cancer Campaign**

Breast Cancer Campaign aims to drive world-class breast cancer research, influence policy and practice, share knowledge and kick-start innovation.

During 2014, Pfizer supported Breast Cancer Campaign with the following:

- We made a donation to fund a policy project that will highlight the good practice required locally to drive up standards of care for breast cancer patients following recent NHS reforms. 

  **£45,000**

During 2014, Pfizer contracted the following services from Breast Cancer Campaign:

- We contracted with Breast Cancer Campaign to chair a policy dinner on the subject of NICE reform.

  **£0**

Total: **£45,000**

As a guide this amount represents less than 1% of the total income of Breast Cancer Campaign based on its last reported financial year (July 2013 - June 2014).

**Breast Cancer Care**

Breast Cancer Care provides information, practical assistance and emotional support for anyone affected by breast cancer.

During 2014, Pfizer supported Breast Cancer Care with the following:

- We made a donation to support three areas of Breast Cancer Care’s work with breast cancer nurses: nursing network news; healthcare professional conference and development of a secondary breast cancer nurse forum.

  **£15,000**

- We made a donation to add to a colleague donation as part of our matched funding programme.

  **£150**

Total: **£15,150**

As a guide this amount represents less than 1% of the total income of Breast Cancer Care based on its last reported financial year (April 2013 - March 2014).

**British Heart Foundation (BHF)**

The BHF is the nation's heart charity and the largest independent funder of cardiovascular research.

During 2014, Pfizer supported the British Heart Foundation with the following:

- We made a donation to add to a colleague donation as part of our matched funding programme.

  **£150.00**

Total: **£150.00**

As a guide this amount represents less than 1% of the total income of the British Heart Foundation based on its last reported financial year (April 2013 – March 2014).
British Lung Foundation

The British Lung Foundation (BLF) exists to help people with lung disease. It does this by raising money to provide services to people with lung disease and their families, to fund scientific research for better treatments and cures and by campaigning for change to improve lung health in the UK. The services provided include Breathe Easy support groups, BLF nurses, BLF active and a helpline.

During 2014, Pfizer supported British Lung Foundation with the following:

<table>
<thead>
<tr>
<th>Description</th>
<th>Sum received by the organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>We engaged BLF to be part of an advisory board meeting to develop a patient focused pathway for molecular diagnostics in lung cancer.</td>
<td>£500</td>
</tr>
<tr>
<td>We engaged BLF to be part of an advisory board meeting to discuss pneumococcal disease and vaccination.</td>
<td>£850</td>
</tr>
<tr>
<td>We supported the ‘Respiratory Health of the Nation’ programme and are an industry partner on the project.</td>
<td>£12,000</td>
</tr>
<tr>
<td>Total:</td>
<td>£13,350</td>
</tr>
</tbody>
</table>

As a guide this amount represents less than 1% of the total income of British Lung Foundation based on its last reported financial year (July 2012 – June 2013).

Cancer52

Cancer52 is an alliance of more than 80 organisations working to address the inequalities that exist in policy, services and research into the less common cancers and to improve outcomes for patients with these highly challenging diseases.

During 2014, Pfizer supported Cancer52 with the following:

<table>
<thead>
<tr>
<th>Description</th>
<th>Sum received by the organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>We provided funding towards Cancer52’s programme of activities related to oncology policy during 2014.</td>
<td>£4,000</td>
</tr>
<tr>
<td>We made a donation towards Cancer52’s Patient Engagement Event for patients with less common cancers.</td>
<td>£4,000</td>
</tr>
<tr>
<td>Total:</td>
<td>£8,000</td>
</tr>
</tbody>
</table>

As a guide this amount represents 11.8% of the total income of Cancer52 based on its last financial year (April 2013 – March 2014).

NB. This percentage reflects the fact that Cancer52 is an umbrella group of patient organisations, and therefore has limited potential to raise funds from diversified sources.

Cancer Campaigning Group

The Cancer Campaigning Group (CCG) is an independent coalition of approximately 60 national cancer charities representing service providers, research, advocacy and campaigning groups for cancer patients and families. The CCG’s aim is to improve cancer policy and services across the six areas of public health and prevention, early diagnosis, treatment, survivorship, commissioning and research.

During 2014, Pfizer supported the Cancer Campaigning Group with the

SHS193 – Date of Preparation March 2015
following:

• We supported the costs associated with the running of the Cancer Campaigning Group. The CCG’s planning is managed by a steering group of six elected cancer charities with the secretariat provided by MHP Communications. As a supporter, Pfizer meets regularly with the steering group to discuss emerging plans.

Total: £6,666.67

As a guide this amount represents 7.8% of the total income of the Cancer Campaigning Group based on its last financial year (January – December 2014).

NB. This percentage reflects the fact that the Cancer Campaigning Group is an umbrella group of patient organisations, and therefore has limited potential to raise funds from diversified sources.

**Cancer Focus NI**

Cancer Focus NI provides help to individuals and families affected by cancer, promotes prevention and awareness, and funds cancer research.

**During 2014, Pfizer supported Cancer Focus NI with the following:**

<table>
<thead>
<tr>
<th>Sum received by the organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>We made a donation to support the delivery of the ENHANCE in Practice Toolkit.</td>
</tr>
<tr>
<td>We supported the organisation’s ‘No Smoking Day 2014’ meeting and received a stand space.</td>
</tr>
<tr>
<td>We supported the organisation’s ‘No Smoking Day 2014’ clinical briefing meeting and received a stand space.</td>
</tr>
</tbody>
</table>

**During 2014, Pfizer contracted the following services from Cancer Focus NI:**

<table>
<thead>
<tr>
<th>Sum received by the organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>We contracted with Cancer Focus NI to provide an expert for a radio awareness day on smoking cessation.</td>
</tr>
<tr>
<td>We arranged and paid for travel and accommodation expenses associated with the radio awareness day.</td>
</tr>
</tbody>
</table>

**Pfizer also provided in-kind support in the following ways:**

• Pfizer provided a copy of the ENHANCE in Practice Toolkit, a support programme designed to help those involved in the provision of smoking cessation services successfully engage smokers with long-term conditions and motivate them to quit.

As a guide this amount represents less than 1% of the total income of Cancer Focus NI based on its last reported financial year (August 2013 – July 2014).

**Cancer Research UK**

Cancer Research UK is a charity that carries out research to improve understanding of cancer and find out how to prevent, diagnose and treat different kinds of cancer, working to improve the lives of all cancer patients and helping people to understand cancer, the progress we are making and the choices that each person can make.
During 2014, Pfizer supported CRUK with the following:

- We made a payment of annual fees relating to the second phase of the Stratified Medicines Partnership programme. **£400,000**
- We sponsored the NCRI Cancer Conference, which is administered by CRUK, a founding member. **£10,000**
- We made two donations to add to a colleague donation as part of our matched funding programme. **£300**

During 2014, Pfizer contracted the following services from CRUK:

- We contracted with CRUK to participate in an experts’ workshop to develop recommendations for the delivery of patient-focused molecular diagnostics pathway for lung cancer. **£500**
- We paid travel expenses for a CRUK staff member to attend the molecular diagnostics pathway workshop £81.30. **£0**

Total: **£410,800**

As a guide this amount represents less than 1% of the total income of CRUK based on its last reported financial year (April 2013 - March 2014).

**Child Growth Foundation**

The Child Growth Foundation is the UK's leading charity relating to children's growth. The charity supports parents with a child who has a diagnosed or suspected growth problem and people who have a growth problem and their families. It also works with medical professionals with an interest in this area of health.

During 2014, Pfizer supported Child Growth Foundation with the following:

- We made a donation in support of the organisation’s members’ conference. **£1,500**

Total: **£1,500**

As a guide this amount represents 1.6% of the total income of Child Growth Foundation based on its last reported financial year (July 2012 - June 2013).

**Children’s Cancer and Leukaemia Group (CCLG)**

Children’s Cancer and Leukaemia Group is a leading children’s cancer charity and the UK and Ireland's professional association for those involved in the treatment and care of children with cancer.

During 2014, Pfizer supported the CCLG with the following:

- We paid to display a stand at paediatric oncology training meeting for healthcare professionals, which was organised by the Children’s Cancer and Leukaemia Group. **£500**

Total: **£500**

As a guide this amount represents less than 1% of the total income of CCLG based on its last reported financial year (January – December 2013).

SHS193 – Date of Preparation March 2015
**Chronic Myeloid Leukaemia Support Group**

The CML Support Group is the UK’s only charity focusing exclusively on people diagnosed with Ph+ Chronic Myeloid Leukaemia. The CML Support Group website was set up in 2000 in order to reach out to all patients diagnosed with CML and to provide support, advice and information to them and their families.

**During 2014, Pfizer contracted the following services from The CML Support Group:**

- A consultancy fee was paid to the CML Support Group for input into a Pfizer education programme for healthcare professionals. **£3,500**

**Total: £3,500**

As a guide this amount represents 7.6% of the total income of the Chronic Myeloid Leukaemia Support Group based on its last reported financial year (January – December 2013).

**Cystic Fibrosis Trust**

Cystic Fibrosis Trust are the only UK-wide charity making a daily difference to the lives of people with cystic fibrosis, and those who care for them.

**During 2014, Pfizer supported Cystic Fibrosis Trust with the following:**

- We made a donation to support the local Havant group in the production and distribution of materials to raise the awareness of cystic fibrosis in their local area. **£650**
- We arranged the donation of an honorarium at the request of a consultant engaged by Pfizer. **£500**

**Total: £1,150**

As a guide this amount represents less than 1% of the total income of Cystic Fibrosis Trust based on its last reported financial year (April 2013 - March 2014).

**Cystitis and Overactive Bladder Foundation**

The Cystitis and Overactive Bladder Foundation (COB Foundation) provides information and support to sufferers of bladder problems, including interstitial cystitis, bacterial cystitis, overactive bladder and urge incontinence.

**During 2014, Pfizer supported the COB Foundation with the following:**

- We made a donation towards the development and printing of information booklets for patient with overactive bladder. **£2,000**

**Total: £2,000**

As a guide this amount represents 3.1% of the total income of the COB Foundation based on its last reported financial year (August 2012 – July 2013).

SHS193 – Date of Preparation March 2015
**Family Planning Association**

Sexual health charity Family Planning Association (FPA) works to establish a society in which everyone has positive, informed and non-judgemental attitudes to sex and relationships; where everyone can make informed choices about sex, relationships and reproduction so that they can enjoy sexual health free from prejudice or harm.

During 2014, Pfizer supported the Family Planning Association with the following:

- We paid a consultancy fee for the organisation’s advice on a public awareness campaign on contraception in Scotland.

<table>
<thead>
<tr>
<th>Sum received by the organisation</th>
<th>£2,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total:</td>
<td>£2,000</td>
</tr>
</tbody>
</table>

As a guide this amount represents less than 1% of the total income of the Family Planning Association based on its last reported financial year (April 2013 – March 2014).

**Fungal Infection Trust**

The Fungal Infection Trust aims are to:

- To promote education about fungal diseases, for example those caused by Candida, Cryptococcus and Aspergillus infections, and also the role of these fungi in allergies
- To support scientific research into these fungi and the illnesses associated with them
- To improve the diagnosis and treatment of fungal illnesses and to support the training of specialised scientists working in this specialised medical area (mycology).

During 2014, Pfizer supported The Fungal Infection Trust with the following:

- We supported the development and maintenance of the Aspergillus website.

<table>
<thead>
<tr>
<th>Sum received by the organisation</th>
<th>£35,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total:</td>
<td>£35,000</td>
</tr>
</tbody>
</table>

As a guide this amount represents 43.2% of the total income of The Fungal Infection Trust based on its last reported financial year (May 2013 - April 2014).

Due to a significant decrease in the annual turnover of the organisation between May 2013 and April 2014 the percentage donated is much higher than estimated at the time of the donation.

**Genetic Alliance UK**

Genetic Alliance UK aims to improve the lives of people affected by genetic conditions by ensuring that high quality services and information are available to all that need them.

During 2014, Pfizer supported Genetic Alliance UK with the following:

- We made a donation to support the organisation’s communication plan to inform member patient groups about the feedback mechanism of the HST consultation.
- We paid for 1 year’s corporate membership of the Genetic Alliance UK Rare Disease industry group Rare Diseases UK.

<table>
<thead>
<tr>
<th>Sum received by the organisation</th>
<th>£3,500</th>
<th>£8,400</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SHS193 – Date of Preparation March 2015
During 2014, Pfizer contracted the following services from Genetic Alliance UK:

- We engaged GAUK to be part of an advisory board meeting to shape a programme of work around improving the commissioning and delivery of molecular diagnostics in lung cancer. £1,650

Total: £13,550

As a guide this amount represents 1.6% of the total income of Genetic Alliance UK based on its last reported financial year (April 2013 - March 2014).

**GIST Support UK**

GIST Support UK provides information, support and education for patients with Gastro-Intestinal Stromal Tumours (GIST), a rare form of cancer. The charity also supports its carers and works closely with healthcare professionals to support research into GIST, and promote awareness, better diagnosis and treatment of GIST.

During 2014, Pfizer supported GIST Support UK with the following:

- We made a donation in support of the organisation’s patient information programme including patient days. £5,000

Total: £5,000

As a guide this amount represents 9.5% of the total income of GIST Support UK based on its last reported financial year (January – December 2013)

**Haemophilia Scotland**

Haemophilia Scotland is a Scottish Charity for people affected by bleeding disorders in Scotland. They provide independent information, direct support, and opportunities for affected people to support each other. By working closely with the Scottish Haemophilia Centres, NHS Scotland, and the Scottish Government they represent the interests of people with bleeding disorders.

During 2014, Pfizer supported Haemophilia Scotland with the following:

- We made a donation in support of the organisation’s membership conference ‘The Gathering’. £7,000
- We made a donation in support of the organisation’s parent mentoring programme which provides peer-to-peer support, particularly for newly or recently diagnosed families. £6,000

Total: £13,000

As a guide this amount represents 17% of the total income of Haemophilia Scotland based on its last reported financial year (January - December 2013).

NB. This percentage reflects the fact that this is a new organisation which is still building its fundraising capacity.
**Independent Cancer Patients’ Voice**

Independent Cancer Patients’ Voice (ICPV) equips cancer patients to inform developments in medical research in the UK to ensure it is led by patients. Through bespoke training of patients as advocates, they are able to bring the opinions, views and experience of cancer patients, their families and carers, to the cancer research community.

During 2014, Pfizer supported ICPV with the following:

- We made a donation to support the organisation’s educational work with lay members to enable them become effective partners in the research process. £3,000

Total: £3,000

As a guide this amount represents 14% of the total income of ICPV based on its last reported financial year (January - December 2013).

**International Alliance of Patient Organisations**

International Alliance of Patient Organisations (IAPO) is a global alliance representing patients of all nations across all disease areas and promoting patient-centred healthcare across the world.

During 2014, Pfizer supported IAPO with the following:

- We paid an annual Healthcare Industry Partnership membership. £30,168
- We supported IAPO’s Latin America regional meeting programme and received delegate places at two meetings and copies of the meeting materials. £12,127

Total: £42,295

As a guide this amount represents 6% of the total income of IAPO based on draft, unaudited accounts. No previous accounts exist as UK charity registration only took place in 2014.

**James Whale Fund for Kidney Cancer**

James Whale Fund for Kidney Cancer (JWF) is a specialist kidney cancer charity. It seeks to help reduce the harm caused by kidney cancer by increasing knowledge and awareness, and providing patient information and support on diagnosis and treatment.

During 2014, Pfizer supported JWF with the following:

- We made a donation towards the running of patient and carer support days in 2014. £8,250
- We made a donation to update and reprint information booklet ‘Understanding Kidney Cancer’. £4,984

During 2014, Pfizer contracted the following services from JWF:

- We contracted with JWF to provide input to a clinicians’ survey about kidney cancer services and patient outcomes. £500

Total: £13,734

SHS193 – Date of Preparation March 2015
As a guide this amount represents 6% of the total income of JWF based on its last reported financial year (October 2012 - September 2013).

**Kidney Research UK**

Kidney Research UK (KRUK) funds live-saving research into kidney disease, increases public awareness of kidney health and seeks to improve quality of life of those affected by the disease.

During 2014, Pfizer supported KRUK with the following:

- We made a donation towards the charity’s AKI Clinical Study Group Meeting.

  £3,000

  Total: £3,000

As a guide this amount represents less than 1% of the total income of KRUK based on its last reported financial year (April 2013 – March 2014).

**Leukaemia CARE**

Leukaemia CARE exists to provide vital care and support to all those whose lives have been affected by leukaemia, lymphoma, myeloma and the allied blood disorders.

During 2014, Pfizer supported Leukaemia CARE with the following:

- We made a donation in support of the organisation’s development and production of a guide to treatments available in the UK for chronic myeloid leukaemia.

  £5,000

  Total: £5,000

As a guide this amount represents less than 1% of the total income of Leukaemia CARE based on its last reported financial year (April 2013 – March 2014).

**Macmillan Cancer Support**

Macmillan Cancer Support improves the lives of people affected by cancer. The charity provides practical, medical and financial support and pushes for better cancer care.

During 2014, Pfizer supported Macmillan Cancer Support with the following:

- We paid for a stand at the 2013 APPG Britain Against Cancer conference.
- We made two donations to add to a colleague donation as part of our matched funding programme.

  £700

  £500

  Total: £1,200

As a guide this amount represents less than 1% of the total income of Macmillan Cancer Support based on its last reported financial year (January – December 2012).
Meningitis Research Foundation

Meningitis Research Foundation funds research to prevent meningitis and septicaemia, and to improve survival rates and outcomes. The charity carries out an information and educational programme for the public and health professionals to reduce death and disability, and offers befriending support and membership of the charity to people affected.

During 2014, Pfizer supported Meningitis Research Foundation with the following:

- We gave a donation to support Meningitis Awareness week. £5,000
- We gave a donation to support a healthcare professional training day. £2,500
- We reimbursed the travel expenses of an MRF colleague attending the launch of the ‘It’s what your child would choose’ Pfizer organised vaccination toolkit launch meeting. £112

Total: £7,612

As a guide this amount represents less than 1% of the total income of Meningitis Research Foundation based on its last reported financial year (April 2013 – March 2014).

National Ankylosing Spondylitis Society (NASS)

NASS is the only UK registered charity dedicated to ankylosing spondylitis (AS). They provide support, advice and information to people with AS and are committed to keeping people as informed as possible about the condition. NASS believe that people who understand their AS and how it should be managed will have the best possible outcome and their vision is for a healthcare system which recognises the signs of inflammatory back pain early and refers people swiftly for a diagnosis.

During 2014, Pfizer supported National Ankylosing Spondylitis Society (NASS) with the following:

- We gave a donation to support the production of a ‘Managing Flares’ factsheet for people with AS. £10,000
- We gave a donation to support the updating and re-print of the NASS patients’ guidebook. £5,000

Total: £15,000

As a guide this amount represents 4.5% of the total income of National Ankylosing Spondylitis Society (NASS) based on its last reported financial year (January – December 2013).

National Association for Pre-Menstrual Syndrome (NAPS)

The National Association for Pre-Menstrual Syndrome (PMS) supports individual PMS sufferers and promotes a greater awareness of PMS and of its treatment.
During 2014, Pfizer supported the National Association for Pre-Menstrual Syndrome with the following:

- We paid to display a stand at a study day on women’s health for healthcare professionals, which was organised by NAPS. £150

Total: £150

As a guide this amount represents 1.6% of the total income of NAPS based on its last financial year (January – December 2013).

**National Rheumatoid Arthritis Society**

The National Rheumatoid Arthritis Society (NRAS) provides support and information for people living with Rheumatoid Arthritis and Juvenile Idiopathic Arthritis, their families, friends and carers, and health professionals who care for them.

During 2014, Pfizer supported NRAS with the following:

- We gave a donation to support a suite of activities focusing on unmet need in Juvenile Idiopathic Arthritis (JIA). This donation was initiated in 2013 but paid in 2014. £30,000
- We gave a donation to support the introduction and training of NRAS Ambassadors in Wales. £2,500
- We gave a donation to support the general costs associated with raising disease awareness and related activities throughout 2014. £5,000
- We engaged NRAS to be part of an advisory board meeting to discuss and advise us on the i-monitor Patient Reported Outcomes tool. £400
- We engaged NRAS to be part of an advisory board meeting to discuss and advise us on patient medication adherence & retention. £400
- We supported the NRAS Annual Conference held in September 2014 at Gomersal Park Hotel, Cleckheaton, West Yorkshire. £1,500
- We supported the JIA@NRAS programme with a donation towards activities specifically for younger people and their families. £15,000
- We engaged NRAS to be part of an advisory group meeting to discuss and advise us on the RA NarRAtive patient / clinician survey. £1,117.07
- We covered the expenses of a member of staff from the organisation to attend a Pfizer meeting on rheumatoid arthritis in Boston Massachusetts, requiring a three night hotel stay:
  - Flight: value - (US$5,137.00) £3,402
  - Food & Beverage: value - (US$294.48) £195
  - Hotel: value - (US$1185.72) £785
  - Ground transportation: value - (US$177.00) £117
- We reimbursed the travel expenses of an NRAS colleague attending a Pfizer organised Parliamentary meeting. £160

Total: £56,077.07

As a guide this amount represents 6.3% of the total income of National Rheumatoid Arthritis Society based on its last reported financial year (January – December 2013),
**National Voices**

National Voices is the coalition of health and social care charities in England. They work to strengthen the voice of patients, service users, carers, their families and the voluntary organisations that work for them.

During 2014, Pfizer supported the National Voices with the following:

- We made a payment to support the organisation’s national members’ conference.

<table>
<thead>
<tr>
<th>Sum received by the organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>£10,000</td>
</tr>
</tbody>
</table>

Total: £10,000

As a guide this amount represents 2% of the total income of National Voices based on its last reported financial year (April 2013 – March 2014).

**NET Patient Foundation**

The NET Patient Foundation provides information and support for people living with, or affected by neuroendocrine tumours. It also raises awareness of neuroendocrine tumours throughout the UK and Ireland, and funds and publicises research into neuroendocrine tumours.

During 2014, Pfizer supported NET Patient Foundation with the following:

- We made a donation in support of the organisation’s project to supply information for patients and healthcare professionals on specialist referrals and treatment of pNET patients.
- We made a donation in support of the organisation’s disease awareness day.
- We made a donation in support of the organisation’s general work in memory of one of our colleagues.

<table>
<thead>
<tr>
<th>Sum received by the organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>£8,000</td>
</tr>
<tr>
<td>£1,633</td>
</tr>
<tr>
<td>£2,000</td>
</tr>
</tbody>
</table>

Total: £11,633

As a guide this amount represents 5.3% of the total income of NET Patient Foundation based on its last reported financial year (October 2012 - September 2013).

**Pain Concern**

Pain Concern is a UK based charity for those living with Chronic Pain and those who care for and about them.

During 2014, Pfizer supported Pain Concern with the following:

- We made a donation in support of the development of an edition of the organisation’s Airing Pain radio show for people living with chronic pain.

<table>
<thead>
<tr>
<th>Sum received by the organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>£3,000</td>
</tr>
</tbody>
</table>

Total: £3,000

As a guide this amount represents 2.3% of the total income of Pain Concern based on its last reported financial year (January - December 2013).
Pain UK

Pain UK aims to bring together every pain charity in the country with the aim of improving the efficiency and effectiveness of member charities by providing training, support and commissioning services; working with others to secure acceptance of pain as an issue in its own right; providing support to people living with pain, where it is not already being provided.

During 2014, Pfizer supported Pain UK with the following:

- We made a donation towards their volunteer training day for their member charities. £3,000

Total: £3,000

As a guide this amount represents 27% of the total income of Pain UK based on its last reported financial year (October 2012 - September 2013).

NB. This percentage reflects the fact that this is a new organisation which is still building its fundraising capacity and is an umbrella group of patient organisations and therefore has limited potential to raise funds from diversified sources.

Parkinson’s UK

Parkinson’s UK is the Parkinson’s support and research charity. They are leading the work to find a cure and improve life for everyone affected by Parkinson’s. The charity brings people with Parkinson’s, their carers and families together and provides them with information, friendship and support. It campaigns to change attitudes and demand better services. Its work is dependent on donations.

During 2014, Pfizer supported the Parkinson’s UK with the following:

- We made a donation to add to a colleague donation as part of our matched funding programme. £150

Total: £150

As a guide this amount represents less than 1% of the total income of the Parkinson’s UK based on its last reported financial year (January - December 2013).

Patients Association

The Patients Association is a national charity providing patients with an opportunity to raise concerns and share experiences of healthcare.

During 2014, Pfizer supported the Patients Association with the following:

- We paid for Corporate Membership of the Patients Association for 2015. In exchange for this, we will receive: two meetings per year with Patients Association senior management team to discuss both organisations’ work and wider health and social care developments; access to reports produced by the Patients Association; opportunity to attend relevant Patients Association receptions; weekly news bulletin via email; sponsorship recognition on the Patients Association website and annual magazine. £10,000

18

SHS193 – Date of Preparation March 2015
During 2014, Pfizer contracted the following services from the Patients Association:

- We contracted the Patients Association to provide patient case studies for a patient facing website developed by Pfizer. £5,000

Total: £15,000

As a guide this amount represents 2.4% of the total income of the Patients Association based on its last reported financial year (January – December 2013).

**PromoCon (Disabled Living)**

PromoCon provides a national service, working as part of Disabled Living, Manchester to improve the life for all people with bladder or bowel problems by offering product information, advice and practical solutions to both professionals and the general public. PromoCon employs a multidisciplinary team of people who work with other services and organisations to develop improvements for people who have continence difficulties.

During 2014, Pfizer supported PromoCon with the following:

- We made a donation towards the development and printing of information leaflets for patient with overactive bladder. £2,000
- We paid to display a stand at an incontinence meeting for healthcare professionals, which was organised by PromoCon. £552

Total: £2,552

As a guide this amount represents less than 1% of the total income of Disabled Living based on its last reported financial year (April 2013 – March 2014).

**Rarer Cancers Foundation**

The Rarer Cancers Foundation offers advice and information to individuals with rare and less common cancers or to families and friends, providing a ‘bespoke’ service by telephone helpline/email/post. The charity receives referrals from other charities, including Macmillan, who are unable to provide the tailored information and advice required. When requested, the forum tries to facilitate networking between patients and/or families affected by the same or similar rarer cancers, putting people in touch with others for support and sharing of experiences and it raises awareness of rare and less common cancers and the needs of patients.

During 2014, Pfizer supported the Rarer Cancers Foundation with the following:

- We made a donation in support of the organisation’s Getting Treatment Guide – a guide for patients seeking access to treatments recommended by their clinician. £6,000
- We paid for membership of the Rarer Cancers Foundation Industry Reference Group for 2014, in return for which we received inclusion on the Rarer Cancers Foundation Industry Reference Group mailing list to receive updates on on-going projects and the opportunity to participate in two meetings of the Group. £12,000
- We made an early payment for membership of the Rarer Cancers Foundation Industry Reference Group for 2015, in return for which we will receive inclusion on the Rarer Cancers Foundation Industry Reference Group mailing list. £12,000

SHS193 – Date of Preparation March 2015
Reference Group mailing list to receive updates on on-going projects and the opportunity to participate in two meetings of the Group.

Total: £30,000

As a guide this amount represents 8.3% of the total income of the Rarer Cancers Foundation based on its last reported financial year (April 2013 – March 2014).

Rose Woodward (Kidney Cancer Support Network)

Rose Woodward is a Founder of Kidney Cancer Support Network (KCSN), a patient-led support network that helps people affected by kidney cancer, their families and friends. As the KCSN is not a registered charity or a company limited by guarantee, Pfizer engaged with Rose Woodward as an individual based on her experience and knowledge working with KCSN.

During 2014, Pfizer contracted the following services from Rose Woodward:

- We contracted with Rose Woodward to provide input to a clinicians’ survey about kidney cancer services and patient outcomes. £500

Total: £500

Roy Castle Lung Cancer Foundation

The Roy Castle Lung Cancer Foundation is the only charity in the UK wholly dedicated to defeating lung cancer, the biggest cancer killer in the world.

During 2014, Pfizer supported Roy Castle Lung Cancer Foundation with the following:

- Pfizer Global is a member of the Global Lung Cancer Coalition (GLCC) for which The Roy Castle Lung Cancer Foundation is the Secretariat. The GLCC is an umbrella organisation that supports lung cancer awareness and best practice sharing among patient groups internationally. Membership includes an annual meeting with the steering group for Pfizer to gain patient group insights and feedback on lung cancer issues. £30,000
- We made a donation in support of the organisation’s disease awareness programme “MegaLungs”. £10,000

During 2014, Pfizer contracted the following services from The Roy Castle Lung Cancer Foundation:

- We paid an honorarium for participation of a staff member to provide the patient perspective at a day-long advisory board on molecular diagnostics. £500
- We paid travel expenses for a member of the Roy Castle Lung Cancer Foundation to attend a roundtable event. £151.90

Total: £40,651.90

As a guide this amount represents less than 1% of the total income of Roy Castle Lung Cancer Foundation based on its last reported financial year (January - December 2013).
Sarcoma UK

Sarcoma UK is the only cancer charity in the UK focusing on all types of sarcoma. Sarcoma UK’s mission is to increase knowledge and awareness of sarcoma through ground-breaking programmes that inspire involvement and transform the landscape for everyone affected by sarcoma.

During 2014, Pfizer supported Sarcoma UK with the following:

- We made a donation in support of the distribution of the organisation’s GP diagnostic tool which aims to improve the recognition of sarcomas.

<table>
<thead>
<tr>
<th>Sum received by the organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>£1,000</td>
</tr>
</tbody>
</table>

Total: £1,000

As a guide this amount represents less than 1% of the total income of Sarcoma UK based on its last reported financial year (April 2013 - March 2014).

Sickle Cell Society

Sickle Cell Society is the only national charity in the UK that supports and represents people affected by sickle cell disease to improve their overall quality of life.

During 2014, Pfizer supported Sickle Cell Society with the following:

- We made a donation in support of the development of the organisation’s patient information leaflet “A Guide to Sickle Cell Disorders”.

<table>
<thead>
<tr>
<th>Sum received by the organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>£1,000</td>
</tr>
</tbody>
</table>

Total: £1,000

As a guide this amount represents less than 1% of the total income of Sickle Cell Society based on its last reported financial year (April 2013 - March 2014).

Skin Conditions Campaign Scotland (SCCS)

Skin Conditions Campaign Scotland (SCCS) is a registered charity dedicated to promoting the interests of people in Scotland, who live with a skin condition of any kind. They operate as an umbrella group campaigning alongside patients and patient groups to improve provision of care for all those affected by skin conditions. They aim to include the views of every person living in Scotland who is affected by, cares for, or cares about skin conditions and shares our aim of improving access to the best possible treatment for all those affected.

During 2014, Pfizer supported Skin Conditions Campaign Scotland (SCCS) with the following:

- We paid for affiliate membership of SCCS for 2014.

<table>
<thead>
<tr>
<th>Sum received by the organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>£2,000</td>
</tr>
</tbody>
</table>

Total: £2,000

As a guide this amount represents 12% of the total income of Skin Conditions Campaign Scotland (SCCS) based on its last reported financial year (October 2012 – September 2013).
Specialised Healthcare Alliance (SHCA)

The Specialised Healthcare Alliance is a broad coalition of patient groups, however does not have charitable status as an organisation itself. The SHCA campaigns on behalf of people with rare diseases and other complex conditions which require specialised medical care. Examples are numerous but include certain cancers, cystic fibrosis, haemophilia, neurological conditions and a wide range of services for children.

During 2014, Pfizer supported The Specialised Healthcare Alliance with the following:

- We paid for annual membership of the organisation. £12,000

Total: £12,000

As a guide this amount represents 7.1% of the total income of The Specialised Healthcare Alliance based on their last reported financial year (January – December 2013).

Stroke Association

The Stroke Association is the only UK wide charity solely concerned with combating stroke in people of all ages. It funds research into prevention, treatment and better methods of rehabilitation, and helps stroke patients and their families directly through its Life After Stroke Services. The Stroke Association also campaigns, educates and informs to increase knowledge of stroke at all levels of society, and acts as a voice for everyone affected by stroke.

During 2014, Pfizer supported the Stroke Association with the following:

- The BMS-Pfizer Alliance made a donation towards the Stroke Association’s Ask First awareness campaign on atrial fibrillation. £20,000*
- The BMS-Pfizer Alliance sponsored the Stroke Association’s UK Stroke Forum healthcare professional conference. £8,500*

During 2014, Pfizer contracted the following services from the Stroke Association:

- The BMS-Pfizer Alliance contracted the Stroke Association to provide an expert speaker for a national radio day on atrial fibrillation. £240*
- The BMS-Pfizer Alliance contracted the Stroke Association to provide expert speakers at four BMS-Pfizer Regional Meetings on Stroke Prevention in Atrial Fibrillation. £3,200*

Total: £31,940

As a guide this amount represents less than 1% of the total income of the Stroke Association based on its last reported financial year (April 2013 – March 2014).

*Amounts shown are Pfizer’s contribution to the total payment from the BMS-Pfizer Alliance, which was 50% in all cases.
The Haemophilia Society

The Haemophilia Society is the only UK-wide charity for everyone affected by a bleeding disorder; a community of individuals and families, healthcare professionals and supporters. For more than 60 years The Society have campaigned for better treatment, been a source of practical information and support, and enabled people living with long-term conditions to lead fulfilling lives, make informed choices about their treatment, care and support and inspire others to do the same.

During 2014, Pfizer supported The Haemophilia Society with the following:

- We made a charitable donation to the organisation for providing a speaker at an internal Pfizer medical training day where they provided insights on living with haemophilia.
  - £111 travel expenses
  - £250 speaker fee
  **£367.60**

- We paid expenses for three members of the organisation in relation to a Pfizer internal event about living with haemophilia.
  - £65.26 travel expenses
  **£65.26**

- We supported the organisation’s AGM meeting through our corporate sponsorship scheme.
  **£4,000**

- We made a charitable donation to support an activity weekend for young people living with haemophilia hosted by the organisation.
  **£10,000**

- We made a charitable donation to support a second activity weekend for young people living with haemophilia hosted by the organisation.
  **£6,500**

- We made a charitable donation for the organisation’s youth worker to attend a Pfizer run train the trainer camp, helping people who run activity events for children and young people living with haemophilia.
  - £250 travel expenses
  **£250**

- We made a charitable donation towards the costs of upgrading and improving the organisation’s website.
  **£5,000**

- We made a charitable donation towards the development of the organisation’s patient network group.
  **£5,000**

- We made a charitable donation to support the organisation’s core activities.
  **£1,200**

**Total: £32,382.86**

As a guide this amount represents 4% of the total income of The Haemophilia Society based on its last reported financial year (October 2012 - September 2013).

Pfizer also provided in-kind support in the following ways:
- Donation of Pfizer haemophilia patient information leaflets (estimated value £540).
- We provided a speaker at the organisation’s AGM to speak about living with haemophilia.

The Pain Relief Foundation

The Pain Relief Foundation was established in response to the need for specialised research into the causes and treatment of chronic pain in humans. The charity aims to carry out research leading to the alleviation of chronic pain, to find improved methods of treating chronic pain, to disseminate the results of such research throughout the world and to work in co-operation with the NHS and universities to provide post-graduate scientific education in chronic pain relief.
During 2014, Pfizer supported the Pain Relief Foundation with the following:

- We paid to display a stand at the European Pain Federation EFIC Winter Cancer Pain School hosted by the organisation. £500
- We paid to display a stand at The Pain Relief Foundation 15th Annual Lecture 2014 hosted by the organisation. £300

Total: £800

As a guide this amount represents less than 1% of the total income of the Pain Relief Foundation based on its last reported financial year (October 2012 - September 2013).

**The Pituitary Foundation**

The Pituitary Foundation is a national support, information and advocacy organisation for pituitary patients, their families, friends and carers. The Foundation operates throughout the UK and the Republic of Ireland.

During 2014, Pfizer supported The Pituitary Foundation with the following:

- We made a donation in support of the production and distribution of the organisation’s 20th anniversary extended edition of the magazine “Pituitary Life” in autumn 2014. To support an informed patients living with pituitary conditions. £2,000

Total: £2,000

As a guide this amount represents less than 1% of the total income of The Pituitary Foundation based on its last reported financial year (July 2012 - June 2013).

**The Rainbow Centre for Conductive Education**

The Rainbow Centre provides Conductive Education for people with motor disorders such as cerebral palsy, Parkinson’s, Multiple Sclerosis, stroke and head injury.

During 2014, Pfizer supported Rainbow with the following:

- We made a donation to this local charity, chosen by Pfizer’s Havant manufacturing site, as part of Pfizer’s Global recognition programme to acknowledge the site’s good work in environmental sustainability planning. £571.23

Total: £571.23

As a guide this amount represents less than 1% of the total income of the Rainbow Centre based on its last reported financial year (July 2012 – June 2013).

**Think Ahead**

Think Ahead are a face to face support charity who help to improve the quality of life of Stroke Survivors and Carers, through awareness, activities and events.
During 2014, Pfizer supported Think Ahead with the following:

- We made a donation to support the organisation’s services for stroke survivors, carers and patients at its Information Centre.

  £246.92

  Total: £246.92

As a guide this amount represents less than 1% of the total income of Think Ahead based on its last reported financial year (April 2013 – March 2014).

**Turner Syndrome Support Society**

Turner Syndrome Support Society is a national charity caring for the needs of those with Turner Syndrome throughout the United Kingdom. The Society offers support and information to both girls and adult women with Turner Syndrome, their families and friends.

During 2014, Pfizer supported Turner Syndrome Support Society with the following:

- We made a donation in support of one of the organisation’s patient information days.

  £1,500

  Total: £1,500

As a guide this amount represents 1.1% of the total income of Turner Syndrome Support Society based on its last reported financial year (January - December 2013).

**UK Lung Cancer Coalition**

The United Kingdom Lung Cancer Coalition (UKLCC) is a partnership of charities, clinicians, senior NHS professionals and healthcare companies with a commitment to doubling lung cancer survival. It is the UK’s only multi-interest group in lung cancer.

During 2014, Pfizer supported UKLCC with the following:

- We paid a membership fee to Red Hot Irons, the appointed Secretariat, for Pfizer to belong to the UKLCC. As a member, we are able to attend members’ meetings and contribute to the strategic and tactical plans for the year (received on 8th May 2014 for 2014 activities).

  £15,000

- We paid a membership fee to Red Hot Irons, the appointed Secretariat, for Pfizer to belong to the UKLCC. As a member, we are able to attend members’ meetings and contribute to the strategic and tactical plans for the year (received on 24th Dec 2014 for 2015 activities).

  £15,000

  Total: £30,000

As a guide this amount represents 21.43% of the total income of UKLCC based on its last reported financial year (January – December 2014).

NB. Due to timings, payment of membership for two years occurred within this financial year.

**Comments:**

- Throughout, we have used description wording provided by the organisations.
- Exchange Rates are taken from the date of payment.

SHS193 – Date of Preparation March 2015